Progress Archives — Skye Bioscience

Spotlight

All

Primers

Perspectives

Progress

Press

Characterizing/Advancing Higher-exposure Dosing

Project Ascend is Skye’s 90-day roadmap to validate higher-exposure dosing for nimacimab and strengthen the clinical and translational evidence behind peripheral CB1 inhibition in obesity.

Released January 3, 2026

CEO 2025 Year in Review

CEO Punit Dhillon discusses Skye's accomplishments in 2025 and execution plans for 2026.

Released December 23, 2025

Third Quarter 2025 Financials & Operational Update

See Skye's Q3 2025 webcast, transcript and news release.

Released November 12, 2025

2025 Stockholder Letter

Skye's 2025 stockholder letter, part of its proxy package, reviews progress, why CB1 matters, and outlook.

Released April 29, 2025

CEO 2024 Year in Review

CEO Punit Dhillon discusses Skye’s accomplishments in 2024 and execution plans for 2025.

Released January 13, 2025